The Sentinel Initiative participates in the COVID-19 Evidence Accelerator led by the Reagan-Udall Foundation and Friends of Cancer Research. This public-private partnership combines the efforts of academic, government, and private-sector organizations that apply data analytics to accelerate the understanding of COVID-19.
This collaborative effort has mobilized major data organizations, government and academic researchers, and health systems to maximize the use of real-world data. As the lead research team in one of the Evidence Accelerator Parallel Analyses workstreams, the Sentinel Natural History of Coagulopathy in COVID-19 workgroup has presented projects and led critical discussions on conducting observational analyses in COVID-19 across organizations. Key presentations to the Evidence Accelerator forum on the Natural History of Coagulopathy in COVID-19 and other Sentinel COVID-19 activities are linked below.
- May 13, 2020: Assessing Natural History, Drug Use and Treatment Impact for COVID-19 in the Sentinel System
- June 23, 2020: Coagulopathy Assessment in Patients with COVID-19: A TriNetX Analysis
- June 23, 2020: Risk of Thromboembolic Events With COVID-19: A Sentinel System Investigation – Potential Aims/Methods
- July 14, 2020: Risk of Thromboembolic Events With COVID-19: A Sentinel System Investigation – Update on Methods
- August 4, 2020: Risk of Thromboembolic Events With COVID-19: A Sentinel System Investigation – Focus on Endpoints
- August 18, 2020: Defining COVID-19 Cohorts in Real-World Data
- September 8, 2020: Assessing Data Source Characteristics in Multi-site Analyses
- October 26, 2020: Natural History of Coagulopathy in COVID-19
- October 27, 2020: Descriptive Assessment of Coagulopathy Among COVID-19 Patients: Feasibility Data Review
- October 6, 2021: Natural History of Coagulopathy in COVID-19
- October 20, 2022: Association of COVID-19 vs Influenza with Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients